Medicenna Therapeutics Corp Stock Profit Margin
| MDNA Stock | CAD 1.66 0.06 3.49% |
Medicenna Therapeutics Corp fundamentals help investors to digest information that contributes to Medicenna Therapeutics' financial success or failures. It also enables traders to predict the movement of Medicenna Stock. The fundamental analysis module provides a way to measure Medicenna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicenna Therapeutics stock.
| Last Reported | Projected for Next Year |
Medicenna | Profit Margin |
Medicenna Therapeutics Corp Company Profit Margin Analysis
Medicenna Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Medicenna Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Medicenna Therapeutics is extremely important. It helps to project a fair market value of Medicenna Stock properly, considering its historical fundamentals such as Profit Margin. Since Medicenna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medicenna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medicenna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Medicenna Therapeutics Corp has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all Canada stocks is 100.0% lower than that of the firm.
Medicenna Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medicenna Therapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medicenna Therapeutics could also be used in its relative valuation, which is a method of valuing Medicenna Therapeutics by comparing valuation metrics of similar companies.Medicenna Therapeutics is currently under evaluation in profit margin category among its peers.
Medicenna Fundamentals
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 96.37 M | ||||
| Shares Outstanding | 78.16 M | ||||
| Shares Owned By Insiders | 22.07 % | ||||
| Shares Owned By Institutions | 12.77 % | ||||
| Number Of Shares Shorted | 33.71 K | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (18.67 M) | ||||
| Net Income | (25.47 M) | ||||
| Cash And Equivalents | 33.6 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 13.94 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 26.75 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (16.26 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | (0.38) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 134.43 M | ||||
| Total Asset | 19.13 M | ||||
| Retained Earnings | (106.45 M) | ||||
| Working Capital | 16.21 M | ||||
| Net Asset | 19.13 M |
About Medicenna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medicenna Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicenna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicenna Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medicenna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Medicenna Stock
| 0.56 | AMZN | Amazon CDR | PairCorr |
| 0.55 | BOFA | Bank of America | PairCorr |
| 0.48 | JPM | JPMorgan Chase | PairCorr |
| 0.41 | BRK | Berkshire Hathaway CDR | PairCorr |
| 0.32 | TD-PFD | Toronto Dominion Bank Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.